Patient preferences for the treatment of chronic pain

Описание: Osteoarthritis and Chronic Low Back Pain are two of the most common chronic pain conditions worldwide. To quantify patients’ perspectives on this unmet need, Pfizer and Lilly conducted a patient preference study in the US and UK. In this 10 March 2022 webinar, Marco Boeri (RTI-HS), Lucy Abraham (Pfizer), Kristin Bullok (Eli Lilly), and Brett Hauber (RTI-HS) described the results of the study and the insights that contribute to the final PREFER recommendations.

00:00 Welcome & introduction - Lucy Abraham (Pfizer)
04:30 Overview of study design & high-level results - Brett Hauber (RTI-HS)
17:26 Methodological findings - Marco Boeri (RTI-HS)
29:01 Quantitative benefit-risk evaluation - Kristin Bullok (Eli Lilly)

For more information about the project visit https://www.imi-prefer.eu/

The Patient Preferences in Benefit-Risk Assessments during the Drug Life Cycle (PREFER) project has received funding from the Innovative Medicines Initiative 2 Joint Undertaking under grant agreement No 115966. This Joint Undertaking receives support from the European Union's Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA).

This video and its contents reflect the PREFER project's view and not the view of IMI, the European Union or EFPIA.